Background: Small studies suggested circulating microRNAs (circmiRs) as biomarkers for Heart Failure (HF). However, standardized approaches and quality assessment are not established, and results have been inconsistent, with little replication between studies. We aimed to implement quality standards to enable comparison between cohorts and assess which circmiRs may add prognostic information in HF. Methods: We measured 15 circmiRs in two independent cohorts totaling >2000 subjects. Cohort I (Barcelona) comprised of n=843 chronic HFrEF patients. Cohort II from Detroit comprised n= 1384 chronic HF patients (892 HFrEF, 492 HFpEF). Each sample was measured in duplicate, and normalized to an abundant and stable circmiR (miR-486-5p). Algorithms were installed to define each circmiR measurement as "valid", "unmeasurable" or "invalid". This allowed inclusion of valid low-level circmiR measurements while reducing noise from false amplification signals. Results: In general, between 20-40% of measurements were "invalid", while miR499a_5p and -208a were "unmeasurable" in the majority of patients in both cohorts. Higher levels of circmiRs-133b, -1254, -622, -208a and -499a_5p were significantly associated with risk of death in both cohorts, with hazard ratios ranging from 1.103 to 1.365 per log increase (p-values 0.001 to 0.05). However, adding these circmiRs to established predictors (age, renal function and NTproBNP) did not further augment the c-stat beyond 0.71 (cohort I) or 0.78 (cohort II). Conclusion: We developed stringent quality assessment for circmiR testing, and for the first time robustly validate the association of circmiRs 208a, -499a_5p, -133b, -1254 and -622 with risk of death in HF patients. However, circmiR levels failed to incrementally improve prognostication offered by current biomarkers, possibly due to the relative high number of invalid measurements. This highlights the shortcomings of current PCR-based technology. Novel technologies under study that improve signal-noise ratios may enhance the prognostic performance of circmiRs. Introduction: Cardiac fibrosis is the leading cause of cardiac dysfunction in patients with diabetes. Currently, there is no effective treatment to prevent the onset of this condition. Inflammation is a hallmark of diabetes associated with heart diseases and TNF-alpha is a key factor involved in inflammation. We tested whether downregulation of TNF-alpha could prevent cardiac fibrosis in diabetic mice. Methods and Results: Diabetes was induced in C57BL/6 mice by injecting streptozotocin (STZ, 55 mg/kg/day) for 5 days. Citrate buffer was injected as control. One week after STZ injection, blood glucose levels significantly increased in diabetic C57BL/6 mice (336 ± 26 mg/dl) compared to control (108 ±21 mg/dl). The increased blood glucose was accompanied by increased cardiac fibrosis (MassionTricrime), and increased TNF-alpha mRNA and protein expression in heart tissue. To assess whether genome editing using a clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system can efficiently introduce loss-of-function mutation into the endogenous TNF-alpha gene in vivo, we constructed lentivirus expressing CRISPR-Cas9 and a CRISPR guide RNA targeting TNF-alpha. The lentivirus particles were transplanted into the mouse myocardium by direct intramyocardial injection at the time of initial induction of diabetes. Within 5 days of administration of the lentivirus, the mutagenesis rate of TNF-alpha in the heart was as high as >50% by surveyor assay. No off-target mutagenesis was detected in other tissues such as lung and liver. The CRISPR/Cas9 based knockdown approach resulted in decreased cardiac fibrosis (MassionTricrime), accompanied by reduced expression of TNF -alpha in heart assessed by PCR, Western blot and immunostaining. No significant change of other inflammatory cytokines including IL-6 was observed in the hearts. Furthermore, the CRISPR/Cas9 approach did not alter cell proliferation (BrdU staining) and cell survival (TUNEL assay) in heart. Conclusion: This study demonstrates that inflammation contributes to cardiac fibrosis via TNF-alpha signaling pathway, and suggests that diabetes related cardiac fibrosis may be prevented by downregulation of TNF-alpha via novel CRISPR-Cas9 approach. Background: Global regulatory mechanisms controlling the complex metabolic remodeling which occurs during the onset of heart failure are still poorly understood. However, recent advances have suggested a synergistic link between epigenetic regulation and cellular metabolism, although how this interplay is carried out in the heart is largely unknown. Our recent analyses of chromatin binding proteins differentially regulated during cardiac hypertrophy and failure identified the histone methyltransferase Smyd1. To determine the role of Smyd1 in the adult myocardium we generated inducible, cardiac-specific Smyd1 knockout (Smyd1-KO) mice, which exhibit cellular hypertrophy, chamber remodeling and cardiac dysfunction. In addition, bioinformatics analysis of transcripts differentially expressed in Smyd1-KO heart tissue, before heart function declined, showed that cellular metabolism was the most perturbed biological process in these animals and suggests that Smyd1 may be a key regulator of energy metabolism. Methods and Results: To investigate this hypothesis we carried out metabolomic and gene expression analysis of Smyd1-KO heart tissue to comprehensively characterize the abundance of energetics-related transcripts and metabolites in these animals. Interestingly, our results revealed systemic dysfunction in energy substrate metabolism characterized by downregulation of fatty acid ß-oxidation (observed as a decrease in PPAR-α, carnitine-palmitoyltransferase I, carnitine transporter OCTN2 and myocardial carnitine content [43% reduction]) and branched-chain amino acid (BCAA) oxidation (observed as a 2-fold accumulation of all BCAAs and the decreased expression of PP2Cm, an key activator of BCAA catabolism). In addition, our results identified a dramatic increase in myocardial lactate and alanine (340% and 170% respectively), concomitant with decreased expression of pyruvate dehydrogenase E1 β, indicative of glycolytic impairment. Conclusion: Overall, this study identifies a novel role for Smyd1 in regulating energy metabolism in the heart and provides key insights into the epigenetic mechanisms modulating metabolic disorders such as heart failure. Introduction: Myocardial injury is one of the major concerns when doxorubicin (DOX) is chronically administered for several weeks and may lead to cardiomyopathy and heart failure. Recently, circulating microRNAs (c-miRNAs) have been suggested as potential biomarkers of myocardial injury and drug-induced cardiotoxicity. However, the potential of c-miRNAs as biomarkers of DOX-induced cardiotoxicity in a clinical setting was not assessed. Therefore, the aim of this study is to evaluate the cardiotoxic effects of DOX on the circulating levels of miR-1, miR-133b, miR-146a, miR-208a, miR-208b and miR-423-5p in breast cancer patients. were undetectable in plasma even after the maximum dose of DOX. Circulating levels of miR-1, miR-133b, miR-146a and miR-423-5p were increased along the treatment reaching its peak at the third cycle (increase of 18,6-fold, 11,51-fold, 10,56-fold and 12,09-fold respectively; P<0,001) and earlier than cTnI (fourth cycle). For further analysis, patients with 2 SD above the mean were grouped as "High cTnI" and compared to the others ("control"). High cTnI group (n= 7) showed a cTnI increase from 6.0±1.6 to 134.0±10.52 whereas from 6.4±0.2 to 31±2.8 pg/ml in the control group (n= 52; P<0,001). No changes in LVEF were observed within or between the groups. Despite all miRNAs analyzed had been upregulated during the treatment, only miR-1 and miR133b (muscle-specific miRNAs) were differently expressed in high cTnI patients showing a positive correlation with cTnI (P<0,05). Respectively, miR-1 and miR-133b were increased by 5,05-fold and 4,46-fold (P<0,05) in high cTnI patients when compared with controls. Conclusion: Circulating miR-1 and miR-133b were upregulated by DOX treatment and correlate with subtle myocardial injury in a "normal heart". These findings may lead to the development of biomarkers to monitor DOX-induced subclinical myocardial injury avoiding its progression to irreversible cardiomyopathy and heart failure. Univ of Akron, Akron, OH Cardiac fibroblast (CF) differentiation into highly contractile and hypersecretory myofibroblasts (myoFibs) is critical for reparative fibrosis following myocardial injury/insult. However, excessive and remote area fibrosis by myoFibs can lead to cardiac dysfunction and eventual heart failure. Recently, we have shown that a mechanosensitive ion channel TRPV4 mediates CF differentiation to myoFib in-vitro. In the present study, we investigated the underlying molecular mechanism and the physiological role of TRPV4 during cardiac remodeling following pressure overload (transverse aortic constriction, TAC), in wild type (WT) and TRPV4 knockout (TRPV4KO) mice. We found that TRPV4KO mice exhibited not only improved survival rates compared to WT, but cardiac function analysis showed preserved ejection fraction and fractional shortening in TRPV4 null mice, post-TAC surgeries. Importantly, we found that TAC induced both interstitial and perivascular fibrosis in WT hearts, which was significantly reduced in TRPV4KO hearts. To understand the molecular mechanism, we isolated CFs from WT and TRPV4KO mouse hearts (mCFs). In vitro, we found that TGF-β1-induced differentiation was completely attenuated in TRPV4KO mCFs compared to WT. Further, TGF-β1 treatment induced activation of RhoA in WT mCFs, which was inhibited by pre-treatment with TRPV4 antagonist, AB159908, suggesting that Rho is downstream of TRPV4 in CF differentiation to myoFibs. Further, our recent results found that both TGF-β1 and pharmacological TRPV4 activator GSK1016790A induced the activation of myocardin-related transcription factor-A (MRTF-A) (nuclear translocation), that was abolished when TRPV4 was inhibited. Furthermore, we found that both TGF-β1 and GSK1016790A induced α-SMA and col1a promoter activities indicating CF differentiation. Finally, we found while pharmacological activation of MRTF-A increased, MRTF-A inhibition attenuated TGF-β1-induced CF differentiation. Taken together, these findings suggest that TRPV4 channels mediate cardiac fibrosis through a mechanosensitive transcriptional (Rho/MRTF-A) pathway, and targeting TRPV4 could offer novel therapeutics for treating cardiac fibrosis. Cedars-Sinai Med Cntr, Los Angeles, CA, Current paradigms hold that, in the heart, mitochondrial fission and fragmentation are the result of pathologic stresses such as ischemia, are an indicator of poor mitochondrial health, and lead to mitophagy and cell death. However, recent studies demonstrate that inhibiting fission also results in cardiac impairment, suggesting that fission is important for maintaining normal mitochondrial homeostasis. As these studies have relied on genetic manipulation of dynamic regulators, the role of fission in normal cardiac physiology is still unclear. In this study, we identify a novel role for mitochondrial fragmentation, as a normal physiologic adaptation to meet the energetic demands of exercise. During acute exercise in mice, there is significant "physiologic" mitochondrial fragmentation in the heart, demonstrated by a 30% increase in mitochondrial number and a 20% decrease in area (electron microscopy). Whereas pathologic fragmentation leads to impaired respiration, physiologic fragmentation increases both basal and maximal respiration by 20% (seahorse oximetry). Similar to pathologic fragmentation, physiologic fragmentation is induced by translocation of Drp1 to the mitochondria; however, unlike pathologic fragmentation, mitochondrial membrane potential and reactive oxygen species are maintained and regulators of mitophagy (PINK1, Parkin, LC3) are downregulated. Inhibition of Drp1 during exercise (using either the Drp1-Fis1 inhibitor P110 or the Drp1 GTPase inhibitor mDivi) prevents mitochondrial fragmentation in the heart, increases glycolytic flux and results in a 40% decrease in exercise capacity, demonstrating the requirement for physiologic mitochondrial fragmentation to meet the energetic demands of exercise. In summary, we have shown that cardiac mitochondrial fragmentation is not limited to pathologic states and can be a component of normal physiological regulation of mitochondrial function during stresses such as exercise. Whether physiologic fragmentation can be harnessed as a treatment of cardiovascular disease remains to be determined, although some of the cardiovascular benefit of exercise could be mediated by such a mechanism. Xpg c/-(αMHC-Xpg) mice were used to study left ventricular (LV) geometry and function. Methods: Xpg -/-(n=18), αMHC-Xpg (n=14) and control wildtype (wt, n=14) mice were sacrificed at the age of 16 wks. LV geometry and function were measured and hypertrophy marker genes were determined by qPCR. Superoxide (O 2 -) production and NOX activity were studied using lucigenin-enhanced chemiluminiscence. NO synthase (NOS) and NADPH Oxidase (NOX) -dependent O 2 -were assessed with L-NAME and VAS2870. In αMHC-Xpg and wt mice (both n=4), molecular imaging was performed to determine apoptosis in the in vivo heart using near infrared fluorescent Annexin V probe. Results: Xpg -/-mice showed reduced growth, followed by body weight loss and shortened lifespan (18 wks). αMHC-Xpg mice exhibited normal growth and body weight gain, but also reduced lifespan (28 wks). At 16 wks, LV function had deteriorated in both Xpg -/-and αMHC-Xpg compared to wt (Table 1) . Total and NOS-dependent O 2 -production was only increased in Xpg -/-. In the presence of NADPH, NOX activity was elevated in both groups, but NOX-dependent O 2 -generation was higher only in Xpg -/-. The relative RNA expression level of atrial natriuretic peptide was increased in both groups, but particularly in αMHC-Xpg. Moreover, αMHC-Xpg showed a marked increase in LV end-diastolic lumen diameter and displayed a marked increase in in vivo cardiac apoptosis (27±2pmol vs. 6±1pmol in wt; p<0.05). Conclusion: Mice with (cardiomyocyte-restricted) loss of DNA-repair protein XPG display a heart failure phenotype, demonstrating that intact DNA repair in cardiomyocytes is critical for maintaining normal cardiac function. Background: Little is known about how perturbations in the ECM microenvironment regulate nonmyocyte function. This study was designed to assess whether deficiency of fibrillin-1, a ubiquitous ECM molecule that is expressed primarily in fibroblast-like cells, renders the heart more vulnerable to mechanical stress. Methods and Results: Baseline cardiac structure and function were indistinguishable between WT and fibrillin-1 deficient (Fbn1C1039G/+) mice. However, after only 1 week of pressure overload induced by transverse aortic constriction (TAC), Fbn1C1039G/+ hearts showed dramatic dilation and dysfunction which progressed in the ensuing 3 weeks. Fbn1C1039G/+:TAC heart mass was profoundly increased compared with WT:TAC (14.1±1.6 vs 6.2±0.1 mg/g, p<0.05) as were myocyte area (224±3 vs 206±4μm2, p<0.05) and fibrosis (fold change to SHAM, 3.3±0.2 vs 1.3±0.3, p<0.05). Though Fbn1 expression increased in Fbn1C1039G/+:TAC and WT:TAC hearts, fibrillin-1 deposition in the ECM microenvironment increased only in WT:TAC which notably had compensated function at study end. Intriguingly, in Fbn1C1039G/+:TAC hearts, pERK1/2 was enhanced selectively in vimentin-positive nonmyocytes, whereas enhanced pSmad2 was found in both nonmyocyte and myocyte cell compartments. Remarkably, treatment pre-and post-TAC with a selective MEK inhibitor of ERK1/2 phosphorylation reversed dysfunction despite chronic load. Furthermore, not only was pERK1/2 normalized but also pSmad2 was normalized in both the nonmyocyte and myocyte cell compartments, fibrosis was reduced, and myocyte area returned to normal, implicating Erk-mediated TGFβ-dependent autocrine/paracrine pathways at play. Lastly, in the WT heart, while Fbn1 expression and deposition were increased during compensated hypertrophy, Fbn1 was significantly decreased in the transition to decompensated function which correlated with increased TGFβ signaling and expression of TGFβ targets. Conclusion: Fibrillin-1 deposition in the nonmyocyte microenvironment is an important cardioprotective adaptation that opposes decompensated heart failure. These findings suggest that manipulation of cell-specific microenvironments may represent a therapeutic target for ameliorating heart failure. Recent evidence indicates the importance of microRNAs in the control of vascular homeostasis. However, little is known about the expression of microRNAs in human perivascular cells, namely microvascular and adventitial pericytes. The latter are attracting much attention owing to their potent pro-healing activity, which reportedly involves microRNA-132. Here, we focus on microRNA-532 as a novel regulator of pericyte function. Adventitial pericytes were isolated from vein leftovers of coronary artery bypass graft surgery (n=7 patients). Using a miRCURY Universal RT microRNA PCR Human array, we found 175 microRNAs expressed in all samples, with 19 of them being differentially regulated by hypoxia. By qPCR, we confirmed that microRNA-532 is downregulated by hypoxia (P<0.0001). We next used a Taqman anti-miR inhibitor to reduce microRNA-532 expression to levels similar to those seen under hypoxia. Inhibition of microRNA-532 resulted in enhanced migratory activity as assessed by scratch assays (1.5-fold, P<0.05), without affecting pericyte proliferation or apoptosis. In vitro Matrigel assay showed microRNA-532-inhibited pericytes have reduced capacity to promote network formation by HUVECs, which was associated with prevalent localization of Dil-labelled pericytes around network branches rather than notches. Furthermore, conditioned media from microRNA-532-inhibited pericytes increase the permeability of HUVEC monolayers. Among microRNA-532 candidate targets, we found leptin to be upregulated following pericyte exposure to hypoxia or microRNA-532 silencing. Studies using leptin-silencing confirmed contribution of this hormone in induction of vascular permeability by hypoxic pericytes. On the other hand, angiopoietin-1, a potent vascular stabilizer produced by pericytes, was remarkably downregulated following microRNA-532 silencing. This effect is indirect as angiopoietin-1 is not a direct target microRNA-532. In summary, microRNA-532 is modulated by hypoxia and involved in the control of pericyte motility, angiogenic activity and modulation of vascular permeability. These data reveal a previously unforeseen role of microRNA-532 in vascular biology. Introduction: The Brugada syndrome (BrS) is a channelopathy with a distinctive ECG pattern reflecting decreased sodium current and increased risk of sudden death. Loss of function variants in the cardiac sodium channel gene, SCN5A, account for ~20% of cases. Reduced channel expression has been proposed as a mechanism in other cases of BrS, but functional experiments that directly link regulatory variants to altered ionic current in BrS or other channelopathies have not been reported. Methods and Results: We identified a family with multiple individuals displaying the BrS ECG, but no rare coding region variants in SCN5A. However, Sanger sequencing of other candidate genes identified a previously unreported non-synonymous variant of unknown significance (G145R) in TBX5; Tbx5 haploinsufficiency in mice produces multiple phenotypes, including reduced Scn5a expression. In TBX5-driven reporter assays, TBX5-G145R reduced luciferase expression compared to wild-type protein. To further establish the functional consequences of TBX5-G145R, we studied cardiomyocytes differentiated from induced pluripotent stem cells (iPSC-CMs) derived from mutation carriers in the family. In BrS iPSC-CMs studied 35 days after cardiomyocyte induction, SCN5A transcript abundance was decreased compared to multiple control lines. Peak sodium current at -30 mV (from a holding potential of -100 mV) was -97.1±36.5 pA/pF (n=8) in the BrS myocytes compared to -211±36.0 pA/pF (n=13 from two unique donors; p<0.05) in controls ( Figure) . Conclusion: These data provide strong evidence that TBX5-G145R causes the Brugada syndrome phenotype in this family by reducing cardiac sodium channel expression. The development of iPSC-CMs has allowed us for the first time to directly link altered ion channel gene expression to a channelopathy, and this approach will therefore enable definition of the role of regulatory elements as causes and modulators of cardiac arrhythmia susceptibility.
Introduction: Cardiac fibrosis is the leading cause of cardiac dysfunction in patients with diabetes. Currently, there is no effective treatment to prevent the onset of this condition. Inflammation is a hallmark of diabetes associated with heart diseases and TNF-alpha is a key factor involved in inflammation. We tested whether downregulation of TNF-alpha could prevent cardiac fibrosis in diabetic mice. Methods and Results: Diabetes was induced in C57BL/6 mice by injecting streptozotocin (STZ, 55 mg/kg/day) for 5 days. Citrate buffer was injected as control. One week after STZ injection, blood glucose levels significantly increased in diabetic C57BL/6 mice (336 ± 26 mg/dl) compared to control (108 ±21 mg/dl). The increased blood glucose was accompanied by increased cardiac fibrosis (MassionTricrime), and increased TNF-alpha mRNA and protein expression in heart tissue. To assess whether genome editing using a clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system can efficiently introduce loss-of-function mutation into the endogenous TNF-alpha gene in vivo, we constructed lentivirus expressing CRISPR-Cas9 and a CRISPR guide RNA targeting TNF-alpha. The lentivirus particles were transplanted into the mouse myocardium by direct intramyocardial injection at the time of initial induction of diabetes. Within 5 days of administration of the lentivirus, the mutagenesis rate of TNF-alpha in the heart was as high as >50% by surveyor assay. No off-target mutagenesis was detected in other tissues such as lung and liver. The CRISPR/Cas9 based knockdown approach resulted in decreased cardiac fibrosis (MassionTricrime), accompanied by reduced expression of TNF -alpha in heart assessed by PCR, Western blot and immunostaining. No significant change of other inflammatory cytokines including IL-6 was observed in the hearts. Furthermore, the CRISPR/Cas9 approach did not alter cell proliferation (BrdU staining) and cell survival (TUNEL assay) in heart. Conclusion: This study demonstrates that inflammation contributes to cardiac fibrosis via TNF-alpha signaling pathway, and suggests that diabetes related cardiac fibrosis may be prevented by downregulation of TNF-alpha via novel CRISPR-Cas9 approach. Junko Shibayama, Dane W Barton, Li Wang, Tatiana N Yuzyuk, James Cox, Alexey V Zaitsev, Sarah Franklin; Univ of Utah, Salt Lake City, UT Background: Global regulatory mechanisms controlling the complex metabolic remodeling which occurs during the onset of heart failure are still poorly understood. However, recent advances have suggested a synergistic link between epigenetic regulation and cellular metabolism, although how this interplay is carried out in the heart is largely unknown. Our recent analyses of chromatin binding proteins differentially regulated during cardiac hypertrophy and failure identified the histone methyltransferase Smyd1. To determine the role of Smyd1 in the adult myocardium we generated inducible, cardiac-specific Smyd1 knockout (Smyd1-KO) mice, which exhibit cellular hypertrophy, chamber remodeling and cardiac dysfunction. In addition, bioinformatics analysis of transcripts differentially expressed in Smyd1-KO heart tissue, before heart function declined, showed that cellular metabolism was the most perturbed biological process in these animals and suggests that Smyd1 may be a key regulator of energy metabolism. Methods and Results: To investigate this hypothesis we carried out metabolomic and gene expression analysis of Smyd1-KO heart tissue to comprehensively characterize the abundance of energetics-related transcripts and metabolites in these animals. Interestingly, our results revealed systemic dysfunction in energy substrate metabolism characterized by downregulation of fatty acid ß-oxidation (observed as a decrease in PPAR-α, carnitine-palmitoyltransferase I, carnitine transporter OCTN2 and myocardial carnitine content [43% reduction]) and branched-chain amino acid (BCAA) oxidation (observed as a 2-fold accumulation of all BCAAs and the decreased expression of PP2Cm, an key activator of BCAA catabolism). In addition, our results identified a dramatic increase in myocardial lactate and alanine (340% and 170% respectively), concomitant with decreased expression of pyruvate dehydrogenase E1 β, indicative of glycolytic impairment. Conclusion: Overall, this study identifies a novel role for Smyd1 in regulating energy metabolism in the heart and provides key insights into the epigenetic mechanisms modulating metabolic disorders such as heart failure.
Circulating miR-1 And miR-133b Correlate With Subclinical Myocardial Injury In Breast Cancer Patients Under Doxorubicin Treatment
Vagner Oliveira-Carvalho, Ludmila R Ferreira, Danielle P Borges, Silvia M Ayub-Ferreira, Mônica S Ávila, Sara M Brandão, Fátima Cruz, Edécio Cunha-Neto, Edimar A Bocchi; Instituto do Coração, São Paulo, Brazil Introduction: Myocardial injury is one of the major concerns when doxorubicin (DOX) is chronically administered for several weeks and may lead to cardiomyopathy and heart failure. Recently, circulating microRNAs (c-miRNAs) have been suggested as potential biomarkers of myocardial injury and drug-induced cardiotoxicity. However, the potential of c-miRNAs as biomarkers of DOX-induced cardiotoxicity in a clinical setting was not assessed. Therefore, the aim of this study is to evaluate the cardiotoxic effects of DOX on the circulating levels of miR-1, miR-133b, miR-146a, miR-208a, miR-208b and miR-423-5p in breast cancer patients. Methods: In brief, 59 female patients (50,02±8,64 age) received 4 cycles of chemotherapy with cumulative doses of 60 mg/m 2 DOX during 12 weeks. Cardiac troponin I (cTnI), LVEF and c-miRNAs were measured before the treatment and every 3 weeks after DOX administration. Results: miR-208a and miR-208b were undetectable in plasma even after the maximum dose of DOX. Circulating levels of miR-1, miR-133b, miR-146a and miR-423-5p were increased along the treatment reaching its peak at the third cycle (increase of 18,6-fold, 11,51-fold, 10,56-fold and 12,09-fold respectively; P<0,001) and earlier than cTnI (fourth cycle). For further analysis, patients with 2 SD above the mean were grouped as "High cTnI" and compared to the others ("control"). High cTnI group (n= 7) showed a cTnI increase from 6.0±1.6 to 134.0±10.52 whereas from 6.4±0.2 to 31±2.8 pg/ml in the control group (n= 52; P<0,001). No changes in LVEF were observed within or between the groups. Despite all miRNAs analyzed had been upregulated during the treatment, only miR-1 and miR133b (muscle-specific miRNAs) were differently expressed in high cTnI patients showing a positive correlation with cTnI (P<0,05). Respectively, miR-1 and miR-133b were increased by 5,05-fold and 4,46-fold (P<0,05) in high cTnI patients when compared with controls. Conclusion: Circulating miR-1 and miR-133b were upregulated by DOX treatment and correlate with subtle myocardial injury in a "normal heart". These findings may lead to the development of biomarkers to monitor DOX-induced subclinical myocardial injury avoiding its progression to irreversible cardiomyopathy and heart failure. Univ of Akron, Akron, OH Cardiac fibroblast (CF) differentiation into highly contractile and hypersecretory myofibroblasts (myoFibs) is critical for reparative fibrosis following myocardial injury/insult. However, excessive and remote area fibrosis by myoFibs can lead to cardiac dysfunction and eventual heart failure. Recently, we have shown that a mechanosensitive ion channel TRPV4 mediates CF differentiation to myoFib in-vitro. In the present study, we investigated the underlying molecular mechanism and the physiological role of TRPV4 during cardiac remodeling following pressure overload (transverse aortic constriction, TAC), in wild type (WT) and TRPV4 knockout (TRPV4KO) mice. We found that TRPV4KO mice exhibited not only improved survival rates compared to WT, but cardiac function analysis showed preserved ejection fraction and fractional shortening in TRPV4 null mice, post-TAC surgeries. Importantly, we found that TAC induced both interstitial and perivascular fibrosis in WT hearts, which was significantly reduced in TRPV4KO hearts. To understand the molecular mechanism, we isolated CFs from WT and TRPV4KO mouse hearts (mCFs). In vitro, we found that TGF-β1-induced differentiation was completely attenuated in TRPV4KO mCFs compared to WT. Further, TGF-β1 treatment induced activation of RhoA in WT mCFs, which was inhibited by pre-treatment with TRPV4 antagonist, AB159908, suggesting that Rho is downstream of TRPV4 in CF differentiation to myoFibs. Further, our recent results found that both TGF-β1 and pharmacological TRPV4 activator GSK1016790A induced the activation of myocardin-related transcription factor-A (MRTF-A) (nuclear translocation), that was abolished when TRPV4 was inhibited. Furthermore, we found that both TGF-β1 and GSK1016790A induced α-SMA and col1a promoter activities indicating CF differentiation. Finally, we found while pharmacological activation of MRTF-A increased, MRTF-A inhibition attenuated TGF-β1-induced CF differentiation. Taken together, these findings suggest that TRPV4 channels mediate cardiac fibrosis through a mechanosensitive transcriptional (Rho/MRTF-A) pathway, and targeting TRPV4 could offer novel therapeutics for treating cardiac fibrosis. 
Physiologic Mitochondrial Fragmentation is a Cardiac Adaptation to Increased Energy Demand
Xpg c/-(αMHC-Xpg) mice were used to study left ventricular (LV) geometry and function. Methods: Xpg -/-(n=18), αMHC-Xpg (n=14) and control wildtype (wt, n=14) mice were sacrificed at the age of 16 wks. LV geometry and function were measured and hypertrophy marker genes were determined by qPCR. Superoxide (O 2 -) production and NOX activity were studied using lucigenin-enhanced chemiluminiscence. NO synthase (NOS) and NADPH Oxidase (NOX) -dependent O 2 -were assessed with L-NAME and VAS2870. In αMHC-Xpg and wt mice (both n=4), molecular imaging was performed to determine apoptosis in the in vivo heart using near infrared fluorescent Annexin V probe. Results: Xpg -/-mice showed reduced growth, followed by body weight loss and shortened lifespan (18 wks). αMHC-Xpg mice exhibited normal growth and body weight gain, but also reduced lifespan (28 wks). At 16 wks, LV function had deteriorated in both Xpg -/-and αMHC-Xpg compared to wt (Table 1) . Total and NOS-dependent O 2 -production was only increased in Xpg -/-. In the presence of NADPH, NOX activity was elevated in both groups, but NOX-dependent O 2 -generation was higher only in Xpg -/-. The relative RNA expression level of atrial natriuretic peptide was increased in both groups, but particularly in αMHC-Xpg. Moreover, αMHC-Xpg showed a marked increase in LV end-diastolic lumen diameter and displayed a marked increase in in vivo cardiac apoptosis (27±2pmol vs. 6±1pmol in wt; p<0.05). Conclusion: Mice with (cardiomyocyte-restricted) loss of DNA-repair protein XPG display a heart failure phenotype, demonstrating that intact DNA repair in cardiomyocytes is critical for maintaining normal cardiac function. Background: Little is known about how perturbations in the ECM microenvironment regulate nonmyocyte function. This study was designed to assess whether deficiency of fibrillin-1, a ubiquitous ECM molecule that is expressed primarily in fibroblast-like cells, renders the heart more vulnerable to mechanical stress. Methods and Results: Baseline cardiac structure and function were indistinguishable between WT and fibrillin-1 deficient (Fbn1C1039G/+) mice. However, after only 1 week of pressure overload induced by transverse aortic constriction (TAC), Fbn1C1039G/+ hearts showed dramatic dilation and dysfunction which progressed in the ensuing 3 weeks. Fbn1C1039G/+:TAC heart mass was profoundly increased compared with WT:TAC (14.1±1.6 vs 6.2±0.1 mg/g, p<0.05) as were myocyte area (224±3 vs 206±4μm2, p<0.05) and fibrosis (fold change to SHAM, 3.3±0.2 vs 1.3±0.3, p<0.05). Though Fbn1 expression increased in Fbn1C1039G/+:TAC and WT:TAC hearts, fibrillin-1 deposition in the ECM microenvironment increased only in WT:TAC which notably had compensated function at study end. Intriguingly, in Fbn1C1039G/+:TAC hearts, pERK1/2 was enhanced selectively in vimentin-positive nonmyocytes, whereas enhanced pSmad2 was found in both nonmyocyte and myocyte cell compartments. Remarkably, treatment pre-and post-TAC with a selective MEK inhibitor of ERK1/2 phosphorylation reversed dysfunction despite chronic load. Furthermore, not only was pERK1/2 normalized but also pSmad2 was normalized in both the nonmyocyte and myocyte cell compartments, fibrosis was reduced, and myocyte area returned to normal, implicating Erk-mediated TGFβ-dependent autocrine/paracrine pathways at play. Lastly, in the WT heart, while Fbn1 expression and deposition were increased during compensated hypertrophy, Fbn1 was significantly decreased in the transition to decompensated function which correlated with increased TGFβ signaling and expression of TGFβ targets. Conclusion: Fibrillin-1 deposition in the nonmyocyte microenvironment is an important cardioprotective adaptation that opposes decompensated heart failure. These findings suggest that manipulation of cell-specific microenvironments may represent a therapeutic target for ameliorating heart failure. 
attention owing to their potent pro-healing activity, which reportedly involves microRNA-132. Here, we focus on microRNA-532 as a novel regulator of pericyte function. Adventitial pericytes were isolated from vein leftovers of coronary artery bypass graft surgery (n=7 patients). Using a miRCURY Universal RT microRNA PCR Human array, we found 175 microRNAs expressed in all samples, with 19 of them being differentially regulated by hypoxia. By qPCR, we confirmed that microRNA-532 is downregulated by hypoxia (P<0.0001). We next used a Taqman anti-miR inhibitor to reduce microRNA-532 expression to levels similar to those seen under hypoxia. Inhibition of microRNA-532 resulted in enhanced migratory activity as assessed by scratch assays (1.5-fold, P<0.05), without affecting pericyte proliferation or apoptosis. In vitro Matrigel assay showed microRNA-532-inhibited pericytes have reduced capacity to promote network formation by HUVECs, which was associated with prevalent localization of Dil-labelled pericytes around network branches rather than notches. Furthermore, conditioned media from microRNA-532-inhibited pericytes increase the permeability of HUVEC monolayers. Among microRNA-532 candidate targets, we found leptin to be upregulated following pericyte exposure to hypoxia or microRNA-532 silencing. Studies using leptin-silencing confirmed contribution of this hormone in induction of vascular permeability by hypoxic pericytes. On the other hand, angiopoietin-1, a potent vascular stabilizer produced by pericytes, was remarkably downregulated following microRNA-532 silencing. This effect is indirect as angiopoietin-1 is not a direct target microRNA-532. In summary, microRNA-532 is modulated by hypoxia and involved in the control of pericyte motility, angiogenic activity and modulation of vascular permeability. These data reveal a previously unforeseen role of microRNA-532 in vascular biology. We identified a family with multiple individuals displaying the BrS ECG, but no rare coding region variants in SCN5A. However, Sanger sequencing of other candidate genes identified a previously unreported non-synonymous variant of unknown significance (G145R) in TBX5; Tbx5 haploinsufficiency in mice produces multiple phenotypes, including reduced Scn5a expression. In TBX5-driven reporter assays, TBX5-G145R reduced luciferase expression compared to wild-type protein. To further establish the functional consequences of TBX5-G145R, we studied cardiomyocytes differentiated from induced pluripotent stem cells (iPSC-CMs) derived from mutation carriers in the family. In BrS iPSC-CMs studied 35 days after cardiomyocyte induction, SCN5A transcript abundance was decreased compared to multiple control lines. Peak sodium current at -30 mV (from a holding potential of -100 mV) was -97.1±36.5 pA/pF (n=8) in the BrS myocytes compared to -211±36.0 pA/pF (n=13 from two unique donors; p<0.05) in controls ( Figure) . Conclusion: These data provide strong evidence that TBX5-G145R causes the Brugada syndrome phenotype in this family by reducing cardiac sodium channel expression. The development of iPSC-CMs has allowed us for the first time to directly link altered ion channel gene expression to a channelopathy, and this approach will therefore enable definition of the role of regulatory elements as causes and modulators of cardiac arrhythmia susceptibility. Background: Diabetes is a major risk factor for cardiovascular diseases. Type 2 diabetic patients have a significantly increased mortality after myocardial infarction compared to non-diabetics, though the underlying mechanisms remain poorly understood. Methods and Results: We investigated the cellular and molecular mechanism of post-infarct left-ventricle remodeling by ligating left-anterior descending artery (LAD) in 12-14 month old T2DM and control mice. Cardiac MRI imaging was performed at baseline, day 7 and 14 post-LAD ligation. Global left ventricular ejection fraction was significantly decreased (21.30 ± 4.8% (n=8) and 35.17 ± 8.525% (n=15) for T2DM and controls, P-value <0.0001) in parallel with increased mortality in T2DM mice compared to controls. Genome-wide mRNA-sequencing analysis (Fold change >1.5 and a P-value of <0.005) identified 1609 genes to be differentially expressed (568 upregulated and 1041 downregulated) in the infracted myocardium of T2DM mice compared to controls. Pathway analysis of differentially expressed genes were enriched for mitochondrial dysfunction, TCA cycle and fatty acid oxidation. Transcription factor analysis showed inhibition of PGC-1a, PGC-1b, ESRRA, ESRRB and TFAM in infarcted myocardium of T2DM mice. Transmission electron microscopy (TEM) analysis showed an altered mitochondrial dynamics (fission and fusion), impaired mitophagy and altered cardiomyocyte death modality in infarcted myocardium of T2DM mice compared to controls. Furthermore, Aim2 and NLRC4 inflammasome were highly activated in infarcted myocardium of T2DM mice compared to controls. Cardiac leukocytes exhibited an altered phenotype as assessed by flow cytometry, associated with impaired neovascularization and increased collagen deposition as assessed by fourier-transform infra-red spectroscopy in infarcted myocardium of T2DM mice. Conclusion: We conclude that an altered mitochondrial dynamics, exaggerated inflammasome activation together with impaired neovascularization responses may contribute to an increased mortality after myocardial infarction in T2DM. Modulation of mitochondrial dynamics together with inhibition of inflammasome activation may offer a novel therapeutic target. Angiogenesis, the growth of new capillaries from pre-existing ones, is regulated by a balance of both mechanical and soluble factors. Important for natural processes such as wound healing and reproduction, insufficient or excessive angiogenesis causes a variety of pathological diseases that affects more than one billion people worldwide. While the mechanism by which angiogenesis occurs is well established, how this process is regulated, more specifically negatively regulated, is not well studied. Here, we show mechanosensitive ion channel TRPV4 negatively regulates angiogenesis. First, we cultured aortic ring explants from wildtype (WT) and TRPV4KO mice, finding a significant increase in the sprouting from TRPV4KO aortic rings. Next, we found that endothelial cells (EC) isolated from TRPV4KO mice (TRPV4KO EC) exhibited increased proliferation, migration, as well as abnormal angiogenesis in vitro compared to their WT counterparts. Further, in vivo Matrigel plug assays revealed an increase in vascular growth in TRPV4KO mice. To determine the molecular mechanism by which TRPV4 regulates angiogenesis, we next focused on Rho/Rho kinase pathway. Intriguingly, we found that TRPV4KO EC showed significantly increased basal Rho activity compared to WT EC. Therefore, we pharmacologically inhibited the Rho pathway with Rho kinase (ROCK) inhibitor, Y-27632, which normalized the abnormal angiogenesis exhibited by TRPV4KO EC in vitro. Finally, Y-27632 treatment, in conjunction with Cisplatin, reduced abnormal tumor angiogenesis and growth exhibited by TRPV4KO mice injected with Lewis Lung Carcinoma cells, suggesting that ROCK inhibition may have normalized the tumor vasculature and improved the delivery of Cisplatin. Taken together, these data suggest that TRPV4 regulates angiogenesis via modulation of Rho/Rho kinase pathway and the loss of TRPV4 negatively contributes to both physiological and pathological angiogenesis. This research has received full or partial funding support from the American Heart Association, Yes. Intramyocardial application of cardiosphere-derived cells (CDCs) and their exosomes improves cardiac function and structure by targeting key pathophysiological processes in the mdx mouse model of Duchenne cardiomyopathy. Cardiac function improves, cardiomyogenesis increases, and oxidative stress, inflammation and fibrosis are blunted after CDC injection into 10-month-old mdx hearts. These changes were associated with a substantial increase in maximal exercise capacity: mdx mice injected with CDCs 3 weeks earlier were able to run on a treadmill for 401±29 m (n=11), while vehicle-injected controls were able to run only 251±18 m (N=11; P<0.001). These changes in exercise capacity appear disproportionate to the CDC-related improvement in cardiac function [ejection fraction at 3 weeks 64±1 (N=12) in CDC-injected mice, vs. 57±1 in vehicle-injected controls (N=12; P<0.001)]. We therefore investigated the possibility that intramyocardial CDC injection might improve the skeletal myopathy. In mdx mice, we injected 10,000 allogeneic mouse CDCs intramyocardially and, 3 weeks later, evaluated fibrosis, oxidative stress and gene expression in diaphragm and limb skeletal muscles. RNA sequencing and bioinformatics revealed concordant inhibition of the NFκB inflammatory pathway in both diaphragm and limb skeletal muscle in CDC-injected mdx mice (P<0.05). This finding mirrored changes in the NFκB pathway seen in CDC-injected mdx hearts. Additionally, expression of Myocd, a major regulator of myogenesis, was markedly elevated in limb tissues (P<0.05). Levels of collagen and HO-1 protein were reduced and increased, respectively, in limb skeletal muscles (p<0.05). Thus, intramyocardial CDC injection unexpectedly improves the skeletal myopathy characteristic of Duchenne muscular dystrophy. These findings motivate a search for factors secreted by CDC-injected myocardium that may mediate systemic improvement. Understanding the heart-muscle axis in mdx mice may help to rationalize the skeletal myopathy associated with common forms of heart failure. Non-alcoholic fatty liver disease (NAFLD) is a common feature associated with metabolic syndrome that is rising in prevalence worldwide. It may potentially develop into more serious liver diseases, but the mechanisms leading to NAFLD are incompletely understood. Glutaredoxin 1 (Glrx) is a small thioltransferase that reverses protein glutathione adducts which mediate redox signaling. Glrx is abundant in the liver but its role in the hepatic pathophysiology is unknown. Here we report that chow fed Glrx-deficient mice (Glrx-/-) develop obesity, hyperlipidemia and hepatosteatosis by eight months of age. In addition, high fat high sucrose diet accelerated the onset of steatosis, which further developed into steatohepatitis manifested by elevated hepatic enzymes in plasma (ALT, AST) and expression of pro-inflammatory cytokines in the liver (TNFα, IL-6, IL-1β). Adenoviral Glrx replenishment in the liver of Glrx-/-mice at corrected hepatosteatosis and plasma lipids, indicating an essential role of hepatic Glrx in protecting against the pathogenesis of steatosis. Expression of key enzymes involved in fatty acid and cholesterol synthesis, such as fatty acid synthase (Fasn), were significantly up-regulated in Glrx-/-mice. In addition, the deacetylase activity of sirtuin-1 (SirT1), an important regulator of lipid metabolism, was decreased in Glrx-/-mice, concomitant with increased reversible oxidation of its regulatory cysteines, suggesting that SirT1 is a target mediating the effects of Glrx on lipogenesis. Altogether, we provide a novel redox-dependent mechanism for regulation of hepatic lipid metabolism, and propose that upregulation of hepatic Glrx may be a beneficial strategy for NAFLD. Objective: Mitochondrial membrane potential and oxidative stress play important roles in vascular smooth muscle cell (SMC) proliferation. We screened and investigated potent mitochondrial transporters in SMC proliferation and neointimal formation. Methods And Results: The wire-injured carotid arteries and uninjured arteries of C57BL/6 mice were collected at 5 days post-injury to perform the transcriptome array. We found that uncoupling protein 2 (UCP2) was significantly upregulated in wire-injured arteries. The qPCR results by guest on October 16, 2017 http://circres.ahajournals.org/ showed that the wire-injury caused an initial increase of UCP2 from day 1 to day 7 postinjury and followed by a decrease below basal level at 14, 21 and 28 days. Treatment of cultured aortic SMCs with PDGF caused gradual downregulation of UCP2. The PDGFinduced proliferation and migration of SMCs were augmented in UCP2-/-cells, while attenuated by adenovirus (Ad)-mediated overexpression of UCP2. Similarly, PDGF-induced mitochondrial hyperpolarization and superoxide production were also enhanced in UCP2-/-SMCs but blunted by UCP2 overexpression. TEMPOL abolished UCP2 ablation-elicited increases in SMC proliferation and migration. By screening the PDGF pathway, we found the phosphorylation of IκB was decreased in Ad-UCP2-transfected SMCs. Western blot results showed that UCP2 overexpression inhibited the NF-κB nuclear translocation. Neointima/ media ratios at 14, 21 and 28 days post-injury were higher in UCP2-/-mice than wildtype mice, whereas the reendothelialization at day 7 and 14 was comparable between the two groups. Oral administration of TEMPOL blocked UCP2 ablation-induced increases in neointimal hyperplasia. Local delivery of Ad-UCP2 inhibited the neointimal formation in wire-injured carotid arteries of C57BL/6 mice and also in balloon-injured carotid arteries of Sprague Dawley rats and New Zealand white rabbits. Furthermore, delivery of Ad-UCP2 to stented arterial wall by using a local drug infusion balloon catheter inhibited in-stent restenosis of swine coronary arteries. Finally, we found that overexpression of UCP2 inhibited neointimal hyperplasia in an organ culture model of human saphenous veins. Conclusions: UCP2 inhibits SMC proliferation, neointimal hyperplasia and restenosis.
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filopodia. Tri-lineage differentiation of SV-APCs coincided with the up-regulation of TPBG transcripts at day 3 post-induction (p<0.05 n=3). SiRNA silencing of TPBG in adventitial, cardiac and skeletal muscle pericytes reduced wound closure in a scratch assay by 47% (p<0.0001 n=5), 38% (p<0.01 n=3), 38% (p<0.05 n=3) respectively compared to controls. Additionally, SiRNA silencing of TPBG in SV-APCs reduced their ability to support network formation by human umbilical vein endothelial cells in a Matrigel assay (40% reduction p<0.01 n=4). Crucial pro-angiogenic molecules MMP2 and MMP9 transcripts were also reduced in the TPBG siRNA-silenced SV-APCs compared to control cells (80% reduction p<0.01 n=4). Conclusion: In this study we have shown for the first time the presence of TPBG within the cardiovascular system and TPBG importance in pericyte migration and promotion of endothelial network formation. TPBG may participate in biological functions of human pericytes instrumental to reparative processes.
